List of Excipients in Branded Drug XYOSTED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Antares Pharma Inc	XYOSTED	testosterone enanthate	54436-250	SESAME OIL

Xyosted Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 12, 2026

Xyosted is a differentiated testosterone-enanthate product that combines a subcutaneous route, a single-dose autoinjector, and an oil-based formulation containing refined sesame oil and benzyl benzoate. Its commercial value comes less from excipient novelty than from the interaction between formulation viscosity, injection volume, device performance, dosing convenience, and regulatory positioning. The strongest opportunities are alternative depot vehicles, lower-volume formulations, device-compatible presentations, and products designed to address sesame-oil sensitivity and injection-site tolerability.

What is Xyosted and how is it formulated?

Xyosted contains testosterone enanthate, an ester prodrug of testosterone, for testosterone replacement in adult males with hypogonadism associated with a medical condition. It is administered once weekly by subcutaneous injection using a single-dose autoinjector [1].

Each autoinjector delivers 0.5 mL at one of three strengths:

Xyosted strength	Testosterone enanthate delivered	Approximate concentration
50 mg	50 mg per 0.5 mL	100 mg/mL
75 mg	75 mg per 0.5 mL	150 mg/mL
100 mg	100 mg per 0.5 mL	200 mg/mL

The labeled inactive ingredients are refined sesame oil and benzyl benzoate [1]. The formulation is preservative-free in the conventional multidose sense because each autoinjector is intended for single use.

The formulation strategy addresses several constraints:

• Testosterone enanthate has limited water solubility.
• The product must remain injectable through a short subcutaneous needle.
• The dose must fit within a 0.5 mL presentation.
• The formulation must remain compatible with the autoinjector, container, needle, and elastomeric components.
• The product must support room-temperature storage and acceptable chemical stability.
• The oil vehicle must provide adequate solubilization without creating excessive viscosity or injection pain.

Why are sesame oil and benzyl benzoate used in Xyosted?

Refined sesame oil is the primary vehicle. Benzyl benzoate functions as a cosolvent and can improve testosterone-enanthate solubility and formulation uniformity. The combination permits a high drug load in a small injection volume [1].

The commercial benefits of this strategy include:

1. A 0.5 mL subcutaneous dose.
2. A relatively high testosterone-enanthate concentration.
3. Weekly administration rather than daily topical dosing.
4. Compatibility with an autoinjector format.
5. Elimination of the transfer and measurement steps required for vial-and-syringe products.

The main formulation liabilities are sesame-oil sensitivity, oil viscosity, potential injection-site discomfort, and dependence on the physical compatibility of the formulation with the delivery device. Patients with known hypersensitivity to sesame oil are specifically relevant to product selection [1].

Benzyl benzoate also creates formulation-development considerations. Its concentration must balance solubilization against tolerability and container compatibility. The vehicle can affect extractables and leachables, elastomer swelling, syringe lubrication, needle force, and autoinjector reliability.

What excipient strategies could improve Xyosted or compete with it?

The most commercially relevant strategies are alternative oil vehicles, improved cosolvent systems, and lower-viscosity formulations.

Alternative oil vehicles

Potential vehicles include medium-chain triglycerides, ethyl oleate, cottonseed oil, castor-oil derivatives, and other pharmaceutically qualified injectable oils. Each option creates a different regulatory and technical profile.

Vehicle strategy	Potential benefit	Primary development risk
Medium-chain triglycerides	Lower viscosity and broad excipient familiarity	Testosterone-enanthate solubility may be inadequate
Ethyl oleate	Lower viscosity and potential injection-force improvement	Oxidative stability and regulatory precedent
Cottonseed oil	Established injectable-oil precedent	Allergenicity, supply consistency, and regional acceptability
Castor-oil derivatives	Strong solubilization potential	High viscosity and injection-site tolerability
Mixed-oil systems	Ability to tune viscosity and solubility	More complex control strategy and comparability package

Replacing sesame oil would not be a simple formulation change. A new vehicle could alter absorption, depot formation, pharmacokinetics, injection-site reaction rates, and dose proportionality. For a product relying on a weekly subcutaneous depot, these changes would likely require substantial comparative pharmacokinetic and local-tolerability evidence.

Cosolvent optimization

A competing formulation could reduce benzyl benzoate concentration by using a different cosolvent or a mixed-solvent system. The objective would be to maintain testosterone-enanthate solubility while reducing viscosity, irritation, or precipitation risk.

Potential approaches include:

• Adjusting the ratio of oil to cosolvent.
• Using a higher-solubility testosterone ester concentration system.
• Developing a supersaturated or controlled-precipitation depot.
• Combining a lower-viscosity oil with a qualified injectable cosolvent.
• Using excipients with stronger precedent in subcutaneous depot injections.

The commercial opportunity is strongest if the change allows the same 50, 75, and 100 mg dose strengths in a smaller injection volume or reduces injection force.

Lower-volume and higher-concentration formulations

Xyosted already uses a compact 0.5 mL presentation. A next-generation product could target a lower volume, but increased concentration can raise risks involving precipitation, viscosity, local tissue exposure, and dose-delivery accuracy.

A 0.25 mL presentation would require either a concentration increase or a new dosing architecture. The technical burden would include:

• Demonstrating complete dose delivery.
• Controlling residual volume in the needle and device.
• Establishing uniformity across the product shelf life.
• Showing comparable systemic exposure.
• Evaluating injection-site tolerability at higher local concentration.
• Validating the device for the revised fill volume.

What formulation patents could protect a Xyosted competitor?

Formulation protection could cover the composition, concentration, excipient ratio, manufacturing process, container closure, or pharmacokinetic profile. The highest-value claims would link the excipient system to a measurable clinical or product-performance result.

Potential claim categories include:

Composition claims

These may cover:

• Testosterone enanthate in a specified concentration range.
• A defined oil vehicle.
• Benzyl benzoate or another cosolvent within a concentration range.
• Water-content limits.
• Antioxidant or oxygen-control systems.
• Specific impurity thresholds.

Device-formulation claims

These may cover the combination of:

• An oil-based testosterone formulation.
• A single-dose autoinjector.
• A defined needle gauge or needle length.
• A specified injection volume.
• Delivery through subcutaneous tissue.
• A dose-completion or end-of-dose indicator.

Pharmacokinetic claims

A product developer may pursue claims directed to:

• Weekly dosing.
• Testosterone exposure within a specified therapeutic range.
• Reduced peak-to-trough fluctuation.
• A defined time to maximum concentration.
• Reduced supraphysiologic peak exposure compared with intramuscular testosterone.

Pharmacokinetic claims can be commercially useful but require careful written-description support and clinical evidence. They also may be more difficult to enforce than composition claims if the competing product uses a different formulation.

Manufacturing and stability claims

Manufacturing claims could protect:

• Dissolution and mixing order.
• Temperature-controlled preparation.
• Filtration conditions.
• Nitrogen purging or oxygen control.
• Filling into the autoinjector.
• Limits on particulate matter, peroxide value, or degradation products.

These claims can create practical barriers even when a competitor avoids the composition claims.

What is the FDA regulatory status of Xyosted?

The FDA approved Xyosted in October 2018 through the 505(b)(2) pathway [2]. The product is approved for testosterone replacement in adult males with hypogonadism associated with a medical condition [1].

Key regulatory characteristics include:

Regulatory issue	Xyosted position
Active ingredient	Testosterone enanthate
Dosage form	Injectable solution
Route	Subcutaneous
Administration	Once weekly
Delivery system	Single-dose autoinjector
Controlled substance	Schedule III
Approval pathway	505(b)(2)
Major safety controls	Blood-pressure increase, erythrocytosis, abuse and dependence, prostate-related warnings

The product’s regulatory differentiation is based on route, formulation, dosing schedule, and device presentation rather than a new molecular entity. A generic or follow-on product would need to address both the drug product and the delivery system.

What is the Orange Book status and exclusivity position for Xyosted?

Xyosted is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, as a prescription drug product containing testosterone enanthate [3]. Orange Book analysis should distinguish:

• FDA marketing exclusivity.
• Listed patents.
• Patent expiration dates.
• Pediatric exclusivity.
• Regulatory exclusivity for the 505(b)(2) approval.
• Litigation-related stays or settlements.

The product received three years of new-drug exclusivity associated with its 2018 approval, subject to the scope of the approved changes and the applicable statutory framework [2,4]. That period is separate from patent term.

The strategic patent question is whether the relevant claims cover only the Xyosted formulation and device or also reach competing subcutaneous testosterone-enanthate products. Composition and device claims are generally more relevant to a direct Xyosted substitute than broad method-of-use claims.

When does Xyosted lose exclusivity?

Xyosted’s regulatory exclusivity period has expired. Commercial entry timing therefore depends primarily on the remaining patent estate, any patent certifications, FDA review, litigation, and the ability of a competitor to produce a therapeutically and technically acceptable product.

For a conventional ANDA, the key barriers are:

1. FDA-listed patents.
2. Paragraph IV certification.
3. Possible patent litigation within the statutory period.
4. A 30-month stay if the statutory conditions are met.
5. Device-related and formulation-related claims.
6. Controlled-substance manufacturing and distribution requirements.

A 505(b)(2) applicant could use a different formulation, route-specific clinical strategy, or device presentation. That pathway may be commercially relevant if the applicant cannot rely on the same formulation or must address clinical differences.

Which companies could challenge Xyosted?

Potential challengers include generic injectable manufacturers, specialty pharmaceutical companies, contract development and manufacturing organizations, and companies with testosterone-replacement portfolios.

The most credible challengers would have capabilities in:

• Sterile oil-based injectable manufacturing.
• High-viscosity filling.
• Autoinjector assembly.
• Controlled-substance compliance.
• Subcutaneous pharmacokinetic development.
• Combination-product regulatory submissions.

Large generic manufacturers may have an advantage in ANDA execution and commercial scale. Specialty companies may have an advantage in device redesign, patient-support programs, and differentiated 505(b)(2) products.

A competitor does not need to duplicate every element of Xyosted. It could compete through a different oil vehicle, a prefilled syringe, a reusable injector, or a different testosterone ester while targeting the same treatment segment.

What generic entry risks exist for Xyosted?

The most likely entry scenarios are:

Scenario 1: Same active ingredient, different presentation

A manufacturer could pursue testosterone enanthate in a vial or prefilled syringe. This would compete on price but would not fully replicate Xyosted’s convenience.

Scenario 2: Same drug, alternative autoinjector

A competitor could develop a subcutaneous testosterone-enanthate autoinjector with a different formulation or device. This would present the highest direct competitive threat.

Scenario 3: 505(b)(2) alternative

A sponsor could develop a different concentration, oil vehicle, injection volume, or dosing interval. The product could avoid selected patents but would likely require clinical bridging.

Scenario 4: Substitution by other testosterone products

Intramuscular testosterone cypionate and testosterone enanthate remain lower-cost alternatives. Oral testosterone undecanoate, nasal testosterone, transdermal products, and long-acting implants compete for patients who prioritize other administration profiles [5].

Xyosted’s protection is strongest where the product’s device and subcutaneous depot behavior create practical differentiation. It is weaker against lower-cost testosterone products that do not need to duplicate the autoinjector experience.

How does Xyosted compare with competing testosterone products?

Product category	Administration	Key commercial advantage	Main limitation
Xyosted	Weekly subcutaneous autoinjector	Home administration and fixed dosing	Cost, sesame-oil sensitivity, controlled-substance restrictions
Testosterone cypionate	Intramuscular injection	Low cost and broad availability	Needle burden and administration by patient or caregiver
Testosterone enanthate vial	Intramuscular injection	Established product and low cost	Less convenient dosing process
Aveed	Long-acting intramuscular testosterone undecanoate	Extended dosing interval	In-office administration and pulmonary oil microembolism monitoring
Oral testosterone undecanoate	Oral	Avoids injections	Food effects, monitoring, and product-specific safety issues
Transdermal gel or patch	Daily topical	No injection	Transfer risk, adherence burden, and variable absorption
Testosterone nasal gel	Intranasal	Localized administration	Multiple daily dosing
Testosterone pellets	Implant	Long duration	Invasive insertion and difficult dose adjustment

Xyosted occupies a convenience-oriented segment between daily topical therapy and clinic-administered long-acting injections.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue four commercial positions.

1. Injectable alternative oils

A supplier with a qualified, low-peroxide, low-variability oil system could target testosterone and other lipophilic depot products. The value proposition would be lower viscosity, improved oxidation control, or improved device performance.

2. Cosolvent systems

A formulation platform that maintains testosterone-enanthate solubility at lower viscosity could support 505(b)(2) development and lifecycle management.

3. Device-compatible excipient packages

Suppliers can provide data on compatibility with:

• Glass cartridges.
• Polymer syringes.
• Elastomeric plungers.
• Needle adhesives.
• Autoinjector lubricants.
• Silicone-oil systems.

Such data can shorten development timelines and reduce combination-product risk.

4. Stability and manufacturing support

Commercial value also exists in excipient systems that reduce peroxide formation, particulate generation, extractables, and filling variability. For an oil-based injectable, supply-chain control and lot-to-lot consistency can be as important as the nominal composition.

How strong is the Xyosted patent estate?

The patent position should be evaluated claim by claim rather than by patent count. The commercially important questions are whether the claims cover:

• The specific testosterone-enanthate and sesame-oil formulation.
• The use of benzyl benzoate as a cosolvent.
• Weekly subcutaneous delivery.
• The 0.5 mL autoinjector presentation.
• Dose strengths of 50, 75, and 100 mg.
• Pharmacokinetic or testosterone-level parameters.
• Manufacturing and filling methods.

A strong estate would combine composition claims with device, method-of-use, and manufacturing claims. A narrower estate would leave room for alternative oil systems, different injection volumes, or prefilled syringe products.

Patent strength is also affected by enablement, written description, obviousness, prosecution history, and the ability to identify infringement from public product information. Device and formulation claims may provide the most immediate commercial leverage, while pharmacokinetic claims may require more complex evidence.

What is the revenue exposure to Xyosted competition?

Revenue exposure depends on how much of the product’s sales derive from convenience rather than active-ingredient differentiation. A low-cost testosterone-enanthate vial can pressure price but may not capture all Xyosted users because it lacks the same delivery experience.

The most damaging competitor would likely combine:

• Testosterone enanthate.
• Subcutaneous administration.
• A ready-to-use presentation.
• A low-viscosity formulation.
• A price materially below Xyosted.
• Broad pharmacy and specialty-distribution access.

An alternative sesame-free formulation could also capture patients who cannot use Xyosted’s labeled vehicle. That opportunity is narrower but could support premium positioning.

Key Takeaways

• Xyosted uses testosterone enanthate in refined sesame oil with benzyl benzoate.
• The formulation supports a 0.5 mL, once-weekly subcutaneous autoinjector.
• The central commercial moat is the formulation-device combination, not excipient novelty alone.
• The strongest excipient opportunities involve lower-viscosity oils, sesame-free vehicles, cosolvent optimization, and device-compatible injectable systems.
• Regulatory exclusivity has expired, so remaining patent claims and technical execution determine entry risk.
• A direct competitor would need to address subcutaneous pharmacokinetics, injection tolerability, sterile oil filling, autoinjector performance, and controlled-substance compliance.
• Biosimilar competition is not the relevant framework. Testosterone enanthate is a small-molecule active ingredient, so generic and 505(b)(2) pathways are more relevant.
• Formulation, device, method-of-use, stability, and manufacturing claims should be analyzed together when assessing the estate.

FAQs

Can Xyosted use a different oil instead of sesame oil?

A competing product can use a different injectable oil, but the change would require evidence addressing solubility, stability, viscosity, pharmacokinetics, local tolerability, and container-device compatibility.

Is benzyl benzoate essential to Xyosted?

Benzyl benzoate is a labeled inactive ingredient and supports the oil-based formulation. It may not be essential to every testosterone-enanthate formulation, but removing or replacing it could change solubility, viscosity, precipitation risk, and absorption.

Is there a biosimilar pathway for Xyosted?

No. Testosterone enanthate is a small-molecule drug. Potential competitors would generally use an ANDA or 505(b)(2) pathway rather than the biosimilar pathway.

Could a sesame-free testosterone autoinjector compete with Xyosted?

Yes. A sesame-free product could target patients with sesame-oil sensitivity or prescribers seeking an alternative vehicle. It would still need to demonstrate comparable product performance and acceptable subcutaneous tolerability.

What is the most valuable formulation improvement for a Xyosted competitor?

A lower-viscosity, sesame-free formulation that preserves weekly exposure in a small-volume autoinjector would offer the clearest commercial differentiation.

References

1. U.S. Food and Drug Administration. (2024). Xyosted (testosterone enanthate) injection prescribing information. Antares Pharma, Inc.

2. U.S. Food and Drug Administration. (2018). FDA approves new testosterone replacement therapy. FDA.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Congress. (2024). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355. Government Publishing Office.

5. American Urological Association. (2018, amended 2022). Evaluation and management of testosterone deficiency guideline. American Urological Association.